MMP9 and ischemic stroke: Thus, studies have demonstrated that a panel of biomarkers, including complement C3, high-sensitive C-reactive protein, hepatocyte growth factor, MMP9, and anti-phosphatidylserine antibodies, can provide more comprehensive risk stratification for adverse outcomes in ischemic stroke [66].